A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition
Status:
Not yet recruiting
Trial end date:
2021-12-06
Target enrollment:
Participant gender:
Summary
This study will be a single-center, randomized, single-dose, open-label, two-treatment,
two-period, two-sequence crossover bioequivalence study to compare the rate and extent of
absorption of WD-1602 granule formulation (WD Pharma) to the reference drug Pradaxa® capsule
(BI, Germany) under fed conditions in healthy subjects.